Characterization of the Azinomycin B Biosynthetic Gene Cluster Revealing a Different Iterative Type I Polyketide Synthase for Naphthoate Biosynthesis  by Zhao, Qunfei et al.
Chemistry & Biology
ArticleCharacterization of the Azinomycin B Biosynthetic
Gene Cluster Revealing a Different Iterative Type I
Polyketide Synthase for Naphthoate Biosynthesis
Qunfei Zhao,1 Qingli He,1 Wei Ding,1,2 Mancheng Tang,1 Qianjin Kang,1,3 Yi Yu,1,3 Wei Deng,1 Qi Zhang,1 Jie Fang,1
Gongli Tang,1 and Wen Liu1,3,*
1State Key Laboratory of Bioorganic and Natural Product Chemistry, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences,
354 Fenglin Road, Shanghai 200032, China
2School of Life Science, Lanzhou University, 222 South Tianshui Road, Lanzhou 730000, China
3Laboratory of Microbial Metabolism and School of Life Science & Biotechnology, Shanghai Jiaotong University, 1954 Huashan Road,
Shanghai 200030, China
*Correspondence: wliu@mail.sioc.ac.cn
DOI 10.1016/j.chembiol.2008.05.021SUMMARY
Azinomycin B is a complex natural product contain-
ing densely assembled functionalitieswith potent an-
titumor activity. Cloning and sequence analysis of the
azi gene cluster revealed an iterative type I polyketide
synthase (PKS) gene, five nonribosomal peptide syn-
thetases (NRPSs) genes andnumerous genes encod-
ing the biosynthesis of unusual building blocks and
tailoring steps for azinomycin B production. Charac-
terization of AziB as a 5-methyl-naphthoic acid (NPA)
synthase showed a distinct selective reduction pat-
tern in aromatic polyketide biosynthesis governed
by bacterial iterative type I PKSs. Heterologous ex-
pression established the PKS-post modification
route from 5-methyl-NPA to reach the first building
block 3-methoxy-5-methyl-NPA. This proposed azi-
nomycin B biosynthetic pathway sets the stage to
investigate the enzymatic mechanisms for building
structurally unique and pharmaceutically important
groups, including the unprecedented azabicyclic
ring system and highly active epoxide moiety.
INTRODUCTION
Azinomycin B (Figure 1), namely, carzinophilin A, originally iso-
lated from Streptomyces sahachiroi (Hata et al., 1954), was sub-
sequently reisolated from S. griseofuscus along with its naturally
occurring analog azinomycin A (Yokoi et al., 1986). Azinomycin B
contains a set of unusual functionalizedmoieties that are densely
assembled in the architecture, including a naphthoate building
block, a 2-amino-1,3-dicarbonyl group, an epoxide moiety,
and an unprecedented aziridino[1, 2a]pyrrolidine (1-azabicy-
clo[3.1.0]hexane) ring system. As a consequence of these struc-
tural features, azinomycin B binds within the major groove of
DNA and forms covalent interstrand crosslinks (ISCs) by electro-
philic attack of C10 and C21 onto N7 positions of suitably
disposed purine bases with apparent sequence selectivity (Arm-
strong et al., 1992; Hartley et al., 2000; Coleman et al., 2002;Chemistry & Biology 1LePla et al., 2005). Recently, in vivo study on DNA damage in
yeast supported the mode of ISC action of azinomycin B (Kelly
et al., 2006), suggesting that the resulting DNA alkylation and
crosslinking are biologically relevant to its potent antitumor
activity.
Initial cytotoxicity studies and early phase clinical investigation
on P388 leukemic mice showed that azinomycin B is highly
active against leukemic cell line L5178Y at the nanomolar level
and provides an increased lifespan (ILS) comparable to the clin-
ically used DNA ISC drug mitomycin C (but with lower dosage)
(Shimada et al., 1955; Ishizeki et al., 1987). Although poor avail-
ability and extreme instability prevented detailed screening of
the scope of the biological activities and development in the clin-
ical trail as the chemotherapeutic agents, extensive efforts on
evaluation of azinomycin analogs have been performed by
chemical synthesis. The total synthesis of azinomycin A was
achieved in 2001 (Coleman et al., 2001), showing a drawback
that the C12 hydroxyl group destabilizes the compound during
isolation. A number of bioactive analogs that are structurally
more stable than the natural products have also been synthesized
(Alcaroet al., 2005;Casely-Hayfordet al., 2005;David-Cordonnier
et al., 2006; Coleman et al., 2007), providing a structure-biological
activity relationship to study for further understanding of the
mechanismsof thenatural productsandpharmaceuticaldevelop-
ment by structural derivation.
Additionally, the unique structure, remarkable antitumor activ-
ity, and novel mode of action have attracted increased research
interests toward the biosynthesis of azinomycins. The densely
assembled functionalities on azinomycins offer a distinct oppor-
tunity to study the biosynthetic strategy for their unprecedented
molecular scaffolds. However, the progress has been largely im-
peded by difficulties in culturing and securing a constant source
of natural products. Recently, a methodology involving a nutri-
ent-starved fermentation was developed and led to remarkable
improvement of the azinomycin B production (Kelly et al.,
2008), significantly facilitating the biosynthetic investigation
in vivo. Previous isotope-labeled feeding experiments (Corre
and Lowden, 2004; Corre et al., 2006; Liu et al., 2006), which
were carried out either in fermentation or in a developed cell-
free system of the producer S. sahachiroi, clearly revealed a
polyketide origin of the naphthoate moiety and suggested the5, 693–705, July 21, 2008 ª2008 Elsevier Ltd All rights reserved 693
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The Azinomycin B Biosynthetic Gene ClusterFigure 1. Natural Products Containing an Aromatic Moiety
Structures of azinomycins (A and B), neocarzinostatin, cholorothricin, maduropeptin, avilamycin and calicheamicin that bear a biocyclic or monocyclic aromatic
polyketide moiety in each.incorporation of amino acids Valine (Val), glutamic acid (Glu)
derivative, and Threonine (Thr) into the tripeptidyl backbone, in-
dicating that a polyketide synthase (PKS)/nonribosomal peptide
synthetase (NRPS) hybrid system might be involved in the
biosynthesis of azinomycin B.
PKSs that are structurally type I but act in an iterative manner
for aromatic polyketide biosynthesis are widely found in fungi
(Shen, 2000). In contrast, the similar PKSs in bacteria comprises
only five members to date (Figures 1 and 6): AviM (Gaisser et al.,
1997) and CalO5 (Ahlert et al., 2002) catalyze the biosynthesis
of monocyclic orsellinic acid (OSA) for avilamycin (AVI) and cal-
icheamicin (CAL), respectively; ChlB1 (Jia et al., 2006) and
MdpB (Van Lanen et al., 2007) catalyze the biosynthesis of 6-
methylsalicyclic acid (6-MSA) for chlorothricin (CHL) and madur-
opeptin (MDP), respectively; and NcsB (Sthapit et al., 2004; Liu
et al., 2005) is the only representative that catalyzes the biosyn-
thesis of bicyclic 2-hydroxyl-5-methyl-naphthoic acid (NPA) for
neocarzinostatin (NCS). According to the structural similarity
and polyketide origin revealed by isotope-labeled experiments,
the biosynthesis of the naphthoate moiety of azinomycin B likely
involves an iterative type I PKS.
Presently, we report access to the biosynthetic machinery of
the azinomycin B in S. sahachiroi NRRL 2485 by cloning the iter-
ative type I PKS gene aziB using our recently developed rapid
PCR approach (Shao et al., 2006). The sequencing of the entire
azi gene cluster allows for assignment of the functions to694 Chemistry & Biology 15, 693–705, July 21, 2008 ª2008 Elseviededuced gene products, providing insights into the biosynthetic
pathway. A number of novel genes were found in this cluster to
encode the highly diverse functionalities of unusual building
blocks, which might be sequentially assembled to afford azino-
mycin B by an unusual NRPS system and tailoring enzymes.
Heterologous expression of aziB in S. albus characterized an
iterative type I PKS AziB for the biosynthesis of a bicyclic aro-
matic polyketide, 5-methyl-NPA, in a manner similar to previ-
ously found 2-hydroxyl-5-methyl-NPA synthase NcsB, but with
distinct selective reduction pattern. Addition of aziB1 (encoding
a P450 hydroxylase) and aziB2 (encoding an O-methyltransfer-
ase) to aziB in S. albus allowed for the production of 3-me-
thoxy-5-methyl-NPA as the first building block for skeleton as-
sembly of azinomycin B. The availability of the azi gene cluster
and proposed biosynthetic pathway will pave the way for further
studies regarding the unusual biochemistry and therefore inspire
attempts to apply this knowledge for combinatorial biosynthesis.
RESULTS
Cloning and Sequencing of the azi Gene Cluster
from S. sahachiroi NRRL 2485
Iterative type I PKSs for aromatic polyketide biosynthesis share
high homology in both amino acid sequence and domain organi-
zation and are phylogenetically distinct from other groups of type
I PKSs (Jenke-Kodama et al., 2008). To specifically probe ther Ltd All rights reserved
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adopted a rapid PCR approach that was developed to access
the 6-MSA synthase gene chlB1 according to the conservedmo-
tifs that are only unique in the iterative type I PKS family (Shao
et al., 2006). With the genomic DNA of S. sahachiroi as the tem-
plate, a distinct product with the expected size of 0.9 kb was
readily amplified and subsequently cloned into pSP72 vector
for sequencing. Analysis of randomly selected clones confirmed
that most of them contained an identical PCR product P1, the
deduced amino acid sequence of which is highly homologous
to the known iterative type I PKSs. To determine the relevance
of P1 to azinomycin B biosynthesis, we set out to inactivate
the target alleles in S. sahachiroi. As expected, the P1 allele
mutant strain AL1001 completely lost the ability to produce azi-
nomycin B (Figures 4A2 and 4BII), confirming that this P1-con-
tained iterative type I PKS gene is involved in the azinomycin B
biosynthesis. Consequently, using the P1 product as a probe,
approximately 6,000 clones of the S. sahachiroi genomic library
were screened, resulting in 12 overlapping cosmids that span
a 50 kb DNA region. To ensure full coverage of the entire azi
gene cluster, additional chromosome walking from the left end
of cosmid pAL1022 was carried out by using the 3.2 kb BamHI
fragment P2 as a probe, eventually leading to a 80 kb contiguous
DNA region on the chromosome, as exemplified by the inserts of
cosmids pAL1022, pAL1023, pAL1024, pAL1025, and pAL1026
(Figure 2A).
The DNA region represented by cosmids pAL1023 and
pAL1024was selected for sequencing, yielding a 63,549 bp con-
tiguous sequence with 71.48% of the overall GC content, char-
acteristic of Streptomyces DNA. Bioinformatic analysis of the
sequenced region revealed 47 ORFs (Figure 2B and Table 1),
34 of which, from aziA3 to aziD2, were proposed to constitute
the azi gene cluster according to functional assignment of their
deduced products. While an approximately 2.0 kb fragment,
within which no apparent ORFs were found, physically sepa-
rated the azi gene cluster from orf(1) that encodes a putative
sporulation protein at the left end, the relatively uncertain right-
side boundary was judged by identification of orf4 encoding a
putative transposase and a set of hypothetic genes (e.g. orf1–3)
that lack significant similarity to those involved in secondary
metabolite biosynthesis.
Genes Encoding the Biosynthesis of Naphthoate Moiety
aziB is the only typical PKS gene identified within the azi gene
cluster, supporting its role in the naphthoate moiety biosynthesis
as outlined in Figure 3A. The deduced product AziB consists of
characteristic domains of type I PKS, including a ketosynthase
(KS), acyltransferase (AT), dehydratase (DH), ketoreductase
(KR), and acyl carrier protein (ACP). It exhibits head-to-tail ho-
mology to the known iterative type I PKSs in bacteria (Figure 6),
including NcsB, ChlB1 and MadB, and AviM and CalO5 (except
the KR domain). In a mechanistic analogy, AziB could be envi-
sioned to catalyze the assembly of a nascent linear hexaketide
from one acetyl-CoA and five malonyl-CoAs by iterative decar-
boxylative condensation as NcsB; however, the KR domain in
AziB may offer additional selective reductions at C3, C5, and
C9 positions (Figure 6IV), which is apparently distinct from the
actions of the KR domain of NcsB occurring at C5 and C9 posi-
tions and the KR domains of ChlB1 and MadB at C5 positionChemistry & Biology 1only. The resulting hexaketide intermediate may then undergo
two intramolecular aldol condensations (between C2–C7 and
C6–C11, respectively) and dehydrations to produce the relatively
hydrophobic aromatic compound 5-methyl-NPA.
To reach 3-methoxy-5-methyl-NPA (1) as the first building
block for assembly of the azinomycin B skeleton, two genes,
aziB1 and aziB2, were identified within the azi gene cluster and
proposed to encode the PKS-post modifications on 5-methyl-
NPA (Figure 3A). AziB1, with high sequence similarity to various
bacterial P450 hydroxylases, might be responsible for introduc-
tion of a hydroxyl group at the C3 position, followed by methyla-
tion with the action of AziB2 that resembles a family of SAM-de-
pendentO-methyltransferases, to render amethoxy functionality.
Genes Encoding the Biosynthesis of Unusual Building
Blocks Derived from Amino Acids
aziC1 encodes a protein belonging to a family of branched chain
amino acid aminotransferases, which catalyze the oxidative
desamination of branched amino acids to form a-keto acids.
Presumably, AziC1 might be responsible for the biosynthesis
of a-ketoisovaleric acid (2; Figure 3B) that serves as the second
building block to be incorporated into the peptidyl backbone of
azinomycin B by NRPS AziA3 (described below).
At least ten genes, aziC2–C11, are assumed to be involved in
the biosynthesis of the third building block, aziridino[1, 2a]pyrro-
lidinyl amino acid (3) as shown in Figure 3C. AziC2 shares high
sequence similarity to LysX that catalyzes the N-acetylation of
2-aminoadipate in the bacterial lysine (Lys) biosynthetic path-
way, suggesting that the first step toward 3 starts with Glu by
protection of the a-amino group. AziC3 and AziC4, respectively
similar to various N-acetylglutamate kinases and phosphate
reductases in the ornithine (Orn) biosynthetic pathways, may
activate the g-carboxyl group of N-acetylglutamic acid by phos-
phorylation and then reduce it to form N-acetylglutamyl-g-semi-
aldehyde. AziC5 and AziC6, both of which, respectively, share
high homologies to the N- and C-terminal subunits of transketo-
lases, could constitute a protein complex with thiamine pyro-
phosphate (TPP) as the cofactor for two-carbon unit extension
on the C5 position. Subsequently, AziC7, resembling members
of a pyridoxal-phosphate-dependent aminotransferase family,
is likely responsible for transamination from Glu onto the
6-keto group, fulfilling all atoms requirement for the azabicyclic
skeleton formation to reach 3.
To validate the role of AziC7 in the azinomycin B biosynthesis,
we inactivated aziC7 by replacing it with an erythromycin resis-
tance gene. As shown in Figure 4, the resultant mutant AL1003
completely lost the ability of producing azinomycin B. Further
HPLC-MS analysis revealed an intermediate exhibiting an
[M  H] ion at m/z = 215.09, consistent with the molecular
formula C13H12O3. With a standard as the control, we confirmed
its identity to 3-methoxy-5-methyl-NPA (Figure S3IV), which was
also accumulated in the wild-type strain fermentation with
a higher yield (partially owing to the decomposition of azinomy-
cin B [Figure S3II]). This finding strongly supported the involve-
ment of AziC7 in the peptidyl backbone formation.
AziC8 exhibits high sequence homology to a family of short
chain acyl-CoA dehydrogenase/reductases, suggesting an
a-b dehydrogenation required to initiate the closing of the first
nitrogen-contained, five-membered ring. Despite no obvious5, 693–705, July 21, 2008 ª2008 Elsevier Ltd All rights reserved 695
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The Azinomycin B Biosynthetic Gene ClusterFigure 2. Cloned DNA Region on the Chromosome of S. sahachiroi and Restriction Map and Genetic Organization of the azi Biosynthetic
Gene Cluster
(A) An 80 kb contiguous DNA locus represented by five cosmids and restriction map. Solid black bars indicate regions whose sequence has been determined.
Solid quadrates indicate the probe loci. B, BamHI.
(B) Genetic organization of the azi gene cluster. Proposed functions of individual orfs are labeled and summarized in Table 1.candidates located in the azi gene cluster, it would be reasonable
that the terminal hydroxyl can be activated (e.g., phosphoryla-
tion) by forming a good leaving group for the closure of the sec-
ond aziridine ring. AziC9 resembles a P450 monooxygenase
family, supporting its action at the C4 position for introduction
of a hydroxyl group. Finally, AziC10, which belongs to a deacy-
lase family, is assumed to catalyze the deacetylation reaction
and release 3 as a key building block for assembly of the azino-
mycin B skeleton.
Noticeably, AziC11 exhibits high sequence homology to vari-
ous discrete PCPs, raising the question of whether enzymatic696 Chemistry & Biology 15, 693–705, July 21, 2008 ª2008 Elseviereactions toward the formation of 3 occur on the free amino
acid or acyl-PCP.
Genes Encoding NRPSs for Assembly
of the Azinomycin B Skeleton
Five modular NRPS genes, aziA1–A5, were found within the azi
gene cluster. As shown in Figure 3D, their deduced products
constitute an atypical NRPS system. AziA1 is a bifunctional en-
zyme with two catalytic activities involving an acyl-CoA ligase
(AL) and peptidyl carrier protein (PCP), presumably responsible
for activating 3-methoxy-5-methyl-NPA 1. The naphthoater Ltd All rights reserved
Chemistry & Biology
The Azinomycin B Biosynthetic Gene Clustermoiety could then be transferred to AziA2, domains in which are
arranged as condensation (C) domain -PCP-C, for initiation of the
azimomycin B skeleton assembly. AziA3 shares high sequence
homology to the N-terminal modules of CesA and CesB with an
AL-ketoreductase (KR)-PCP organization in each (Magarvey
et al., 2006), which were characterized to govern the a-keto
acid activation, tethering, and reduction in the cereulide biosyn-
thesis. Similarly, AziA3 could activate the a-ketoisovaleric acid
2 and transfer it onto thePCPdomain, and the internal KRdomain
may perform the ketoreduction to form a-hydroxyisovaleryl moi-
ety. Although structurally AziA4 is similar to typical NRPS mod-
ules composed of C-A-PCP domains, the A domain of AziA4
should be novel due to the recognition of the aziridino[1, 2a]pyr-
rolidinyl amino acid 3 as the substrate. The last NRPSAziA5 is the
only tetradomain protein in the azinomycin B assembly system,
containing an additional reductase (RE) domain appended to
C-A-PCP at the C terminus. Similar RE domains of NRPSs have
been shown to release the resultant peptidyl intermediates as
reductive products instead of the more commonly found thioes-
terase (TE) domains for hydrolysis, lactamization, or lactonization
(Kopp and Marahiel, 2007). Thus, the C-terminal AziA5-RE
domain may function in this manner to form an aldehyde.
To predict the substrates of the azinomycin B NRPS system,
the eight specificity-conferring codes for each A or AL domain
(except the AziA3-AL, which apparently lacks these codes)
were identified as follows by sequence alignment with the A do-
main of PheA (Stachelhaus et al., 1999; Challis et al., 2000):
GIHTTGSQIK for AziA1-AL; DVFDFGGVCK for AziA4-A; and
DFWSVGMVHK for AziA5-A. While all available models showed
negative results for AziA1-AL and AziA4-A (consistent with an
unusual substrate incorporated in each described above),
AziA5-A was supposed to recognize and activate Thr, which
may serve as the fourth building block (4) for assembly. As a con-
sequence, these azinomycin B NRPSs are hypothesized to se-
quentially condense building blocks 1, 2, 3, and 4, involve forma-
tions of one ester bond and two amide bonds, and finally release
the putative key intermediate as an aldehyde, pre-azinomycin B,
as shown in Figure 3D.
To support the NRPS function, we chose aziA3, which resides
in the left end of the azi gene cluster, for inactivation. As ex-
pected, the resultant mutant AL1002 failed to produce azinomy-
cin B (Figures 4A3 and 4BIII), confirming its need for azinomycin
B biosynthesis. Surprisingly, several attempts failed to detect the
intermediates such as 3-methoxy-5-methyl-NPA accumulated in
the mutant AL1002 fermentation (Figure S3V).
Three discrete TE genes, aziA6, -A7, and -A8, were identified
within the azi gene cluster. aziA6 and A7 are genetically linked
with the NRPS genes aziA3 and aziA4 (in particular, aziA6 is likely
to be translationally coupled with these NRPS genes in a 12 kb
large operon as judged by overlapping of their start and stop co-
dons, shown in Figure 2B), supporting their functions associated
with the peptidyl assembly of azinomycin B. Although their
detailed roles remain to be determined, we suggest that AziA6,
A7 and A8 may be involved in (1) improvement of the efficiency
of product formation by regenerating misacylated NRPSs
(Schwarzer et al., 2002), and (2) physiological competition with
the action of AziA5-RE domain to release the intermediate as an
acid, on which further modifications including decarboxylation
at the C3 position might be carried out to produce azinomycin A.Chemistry & Biology 1Genes Encoding Tailoring Enzymes
To eventually produce azinomycin B, post-modifications (includ-
ing acetylation and oxidations) are postulated to proceed with
a set of tailoring enzymes encoded by aziD1, D2, and D3 as
outlined in Figure 3D. AziD1, highly homologous to a family of
O-acyltransferases, may be responsible for acetylation of the
hydroxyl group at C13 position. AziD2, sharing high sequence
similarities to an unknown family of acyl-CoA dehydrogenases,
might be a candidate for oxidation of the hydroxyl group to ren-
der the 2-amino-1,3-dicarbonyl group. In contrast, AziD3, which
resembles members of the mitochondrial acyl-CoA dehydroge-
nase family (using FAD as the cofactor), is likely to be regiospe-
cifically involved in the dehydrogenation at C20-21 to formadou-
ble bond, which could be further oxidated to form the highly
active epoxide fragment in this molecule.
Genes Encoding Resistance and Other Functions
AziE resembles a family of proteins that were widely found in
secondary metabolism and annotated as transmembrane trans-
porters, such as Hyp19 in hygromycin biosynthesis (Palaniappan
et al., 2006). AziE may function as a resistant protein to carry the
synthesized product out of the cells.
Five genes within the azi gene cluster encode proteins whose
functions cannot be assigned in the proposed azinomycin B bio-
synthetic pathway. AziF resembles SimX2-like proteins of un-
known functions in a few antibiotic biosynthetic pathways, such
as ChlI (46% identity) in CHL biosynthesis (Jia et al., 2006).
AziG, belonging to a thioesterase superfamily, shares a hotdog
fold region withmembers that have related catalytic activities, in-
cludingPaaD (28% identity) involved in thebenzoate degradation
(Di Gennaro et al., 2007). A subset of genes, aziH1, aziH2, and
aziH3, encode proteins that share high similarities to enzymes
regarding the first two reaction steps of sulfur metabolism (e.g.,
CysD, CysN, and CysC in E. coli; Leyh et al., 1988).
Finally, three downstream genes of aziB, aziU1–U3, which are
likely to be translationally coupled as judged by their overlapped
start and stop codons, could not be predicted upon sequence
analysis alone. Their involvement in the azinomycin B biosynthe-
sis remains to be determined.
Establishment of the Naphthoate Pathway
by Heterologous Overexpression
The involvement of AziB in azinomycin biosynthesis was con-
firmed by gene inactivation. To verify its function as a novel
naphthoate synthase, a construct that carries aziB alone under
the control of the constitutive promoter PermE* was introduced
into the heterologous host S. albus, yielding the recombinant
strain AL1004. With the S. albus strain AL1006 that carries the
vector pTGV-2 as a negative control, AL1004 was cultured and
analyzed by HPLC (Figure 5II), revealing a distinct peak with a
retention time at 19.6 min. To elucidate the structure, the result-
ing compound was extracted and purified. EI-HRMS analysis of
the obtained powder exhibited anM+ ion atm/z = 186.0675, con-
sistent with themolecular formula C12H10O2. In addition,
1HNMR
spectrum analysis supported that this compound is 5-methyl-
NPA. This finding unambiguously confirmed AziB as an iterative
type I PKS for the biosynthesis of the bicyclic aromatic com-
pound 5-methyl-NPA, other than NcsB for the biosynthesis of
2-hydroxyl-5-methyl-NPA.5, 693–705, July 21, 2008 ª2008 Elsevier Ltd All rights reserved 697
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Gene Sizea Protein Homologb and Origin Similarity/Identity, % Proposed Function
orf(1)c 143 SpoIIE (CAK50935), from
S. ambofaciens ATCC 23877
75/62 Stage II sporulation protein E (SpoIIE)
aziA3 1263 CesA (ABK00751), from
Bacillus cereus
60/41 NRPS (AL-KR-PCP)
aziA6 273 GrsT (YP_001106480), from
Saccharopolyspora erythraea
NRRL 2338
57/41 Thioesterase
aziA4 1103 EndB (ABD65957), from
S. fungicidicus
50/38 NRPS (C-A-PCP)
aziA7 250 TeLB (AAT45287), from
S. tubercidicus
65/52 Thioesterase
aziB2 345 Strop_0204 (YP_001157067), from
Salinispora tropica CNB-440
64/50 O-methyltransferase
aziB1 401 Haur_3696 (YP_001546460), from
Herpetosiphon aurantiacus ATCC
23779
48/31 Cytochrome P450 hydroxylase
aziA1 627 NosC (AAF17280), from Nostoc
sp. GSV224
53/37 NRPS (AL-PCP)
aziE 466 Hyp19 (ABC42556), from
S. hygroscopicus
30/50 Export protein
aziA2 1115 NosD (AAF17281), from Nostoc
sp. GSV224
45/30 NRPS (C-PCP-C)
aziH2 435 CysN (NP_417231), from E. coli 47/63 Sulfate adenylyltransferase subunit 1
aziH1 270 CysD (NP_417232), from E. coli 46/63 Sulfate adenylyltransferase subunit 2
aziH3 185 CysC (NP_417230), from E. coli 41/59 Adenylylsulfate kinase
aziG 133 Strop_1904 (YP_001158744), from
S. tropica CNB-440
66/55 Thioesterase
aziF 62 SimX2 (AAK06794), from
S. antibioticus
55/47 SimX2-like protein
aziD1 403 Srm6* (CAM96572), from
S. ambofaciens
56/42 O-acyltransferase
aziC11 87 PPA1287 (YP_055995), from
Propionibacterium acnes
KPA171202
58/36 PCP/ACP
aziC6 340 TktC (NP_561213), from
Clostridium perfringens str. 13
61/41 Transketolase C-terminal subunit
aziC5 311 TM0954 (NP_228762), from
Thermotoga maritima MSB8
61/44 Transketolase N-terminal subunit
aziC7 440 OleN2 (AAD55458), from
S. antibioticus
53/43 Aminotransferase
aziC4 307 ArgC (YP_604156), from
Deinococcus geothermalis DSM
11300
55/45 N-acetyl-g-glutamyl-phosphate reductase
aziC3 292 TTC1541 (YP_005510), from
Thermus thermophilus HB27
55/36 N-acetylglutamate kinase
aziC10 376 Caur_1204 (YP_001634822), from
Chloroflexus aurantiacus J-10-fl
54/40 N-acetyl-ornithine/N-acetyl-lysine
deacetylase
aziC8 272 ORF39 (ABD65959), from
S. fungicidicus
63/47 Acyl-CoA dehydrogenase/reductase
aziA5 1541 SfmC (ABI22133), from
S. lavendulae
30/42 NRPS (C-A-PCP-RE)
aziB 1779 NcsB (AAM77986), from
S. carzinostaticus subsp.
neocarzinostaticus
66/52 Iterative type I PKS (KS-AT-DH-KR-ACP)698 Chemistry & Biology 15, 693–705, July 21, 2008 ª2008 Elsevier Ltd All rights reserved
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Gene Sizea Protein Homologb and Origin Similarity/Identity, % Proposed Function
aziU1 257 Orf(12) (AAN85502), from
S. atroolivaceus
50/32 Unknown protein
aziU2 221 Rxyl_2597 (YP_645326),
from Rubrobacter xylanophilus
DSM 9941
47/30 Unknown protein
aziU3 337 SMb20513 (NP_437034), from
Sinorhizobium meliloti 1021
42/25 Unknown protein
aziC2 287 Rcas_3469 (YP_001433537),
from Roseiflexus castenholzii
DSM 13941
61/44 Lysine biosynthesis enzyme LysX
aziC1 243 At5g27410 (Q9ASR4), from
Arabidopsis thaliana
43/28 Branched-chain-amino-acid
aminotransferase
AziC9 419 CypLB (AAT45286), from
S. tubercidicus
58/39 Cytochrome P450 hydroxylase
aziA8 249 BorB (CAE45660), from
S. parvulus
54/40 Thioesterase
aziD3 382 MAV_1338 (YP_880582), from
Mycobacterium avium 104
53/33 Acyl-CoA dehydrogenase
aziD2 333 Acd_9 (YP_326591), from
Natronomonas pharaonis
DSM 2160
37/25 Acyl-CoA dehydrogenase
orf1c 371 Nfa26740 (YP_118885), from
Nocardia farcinica IFM 10152
62/50 Unknown protein
orf2c 175 SACE_4220 (YP_001106414),
from Sac. erythraea NRRL 2338
73/62 Unknown protein
orf3c 128 Franean1_6978 (YP_001511217),
from Frankia sp. EAN1pec
63/52 Unknown protein
orf4c 207 Mmc1_2644 (YP_866546), from
Magnetococcus sp. MC-1
54/40 Transposase
orf5c 249 ECA0747 (YP_048859), from
Erwinia carotovora subsp.
Atroseptica SCRI1043
71/59 Short chain dehydrogenase
orf6c 249 SACE_4949 (YP_001107140),
from Sac. erythraea NRRL 2338
91/84 Short-chain dehydrogenase/reductase
orf7c 199 SACE_4948 (YP_001107139),
from Sac. erythraea NRRL 2338
88/83 TetR-family transcriptional regulator
orf8c 151 StPAI005 (AAW49299), from
S. Turgidiscabies
60/47 Unknown protein
orf9c 137 Orf2 (BAF46969), from S. griseus 78/63 Transcriptional regulator
orf10c 286 SAML0296 (CAJ89283), from
S. ambofaciens ATCC 23877
62/45 Dehydrogenase
orf11c 493 SCO2878 (NP_627106), from
S. coelicolor A3(2)
47/30 Unknown protein
orf12c 198 SAV_5747 (NP_826924), from
S. avermitilis MA-4680
89/81 Two-component system response
regulator
aNumbers are in amino acids.
bNCBI accession numbers are given in parentheses.
corfs beyond the azi gene cluster.Further, the constructs harboring mutant aziB, in which site-
specific mutations were performed for inactivating the KR and
DH domains, respectively, were introduced into S. albus, yield-
ing the recombinant strain AL1007 (to express the KR mutant
AziB, G1398A within the NADPH-binding motif GxGxxG),
AL1008 (to express the KR mutant AziB, Y1549F at the con-
served active site), and AL1009 (to express the DH mutantChemistry & Biology 15AziB, H935F within the conserved motif HxxxGxxxxP). Upon
HPLC-MS analysis (Figure 5), AL1007, AL1008, and AL1009
failed to produce 5-methyl-NPA, confirming that the reductive
and dehydrating actions governed by the KR and DH domains
of AziB are essential for the 5-methyl-NPA formation.
To establish the entire biosynthetic pathway for the building
block 1, a construct that carries aziB along with aziB1 (encoding, 693–705, July 21, 2008 ª2008 Elsevier Ltd All rights reserved 699
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The Azinomycin B Biosynthetic Gene ClusterFigure 3. Proposed Biosynthetic Pathway of Azinomycin B
(A–C) Pathways for building blocks (A) 3-methoxy-5-methyl-NPA (1); (B) a-ketoisovaleric acid (2); and (C) aziridino[1, 2a]pyrrolidinyl amino acid (3).
(D) A mode for NRPS-directed skeleton assembly and tailoring modifications.700 Chemistry & Biology 15, 693–705, July 21, 2008 ª2008 Elsevier Ltd All rights reserved
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The Azinomycin B Biosynthetic Gene Clustera putative P450 hydroxylase) and aziB2 (encoding a putative
O-methyltransferase) was introduced into S. albus, yielding the
recombinant strain AL1005. Again with AL1006 as a negative
control, HPLC-MS analysis revealed a distinct compound with
an [M  H] ion at m/z = 215.09 (Figure 5IV), and the identity of
3-methoxy-5-methyl-NPA was confirmed by EI-HRMS analysis
(M+ ion at m/z = 216.0782) and using the synthesized compound
as a standard. These results not only confirmed the assigned
functions of aziB1 and B2 upon sequence analysis, but also
strongly supported the building block 3-methoxy-5-methyl-
NPA as the substrate of NRPS AziA1 for skeleton assembly of
azinomycin B.
DISCUSSION
Polyketide metabolites are biosynthesized by PKSs in a manner
resembling fatty acid synthases. In bacteria, reduced polyketide
(i.e., macrolide, polyene, and polyether) biosynthesis usually re-
quires noniterative type I PKSs, which are giant multifunctional
enzymes that function by following a colinearity rule. Recently,
the emergence of many novel type I PKS systems has become
apparent in publications (reviewed in Shen, 2003; Walsh, 2004;
Wenzel and Muller, 2005), revealing a rich variety of chemistry
and architecture of PKSs beyond our previous understanding.
For example, a specific module in PKSs could be iteratively
used (e.g., borrelidin and aureothin biosynthesis), and single
module-contained PKSs can act iteratively for complex struc-
tural moieties biosynthesis (e.g., enediyne cores and unsatu-
rated fatty acids).
Upon sequence comparison and heterologous expression in
S. albus (Figure 5), the finding of AziB as a 5-methyl-NPA syn-
thase not only adds a new member to the pool of bacterial
Figure 4. Functional Validation of Genes
Involved in Azinomycin B Biosynthesis
(A) Determination of azinomycin B production by
assaying the antibacterial activity againstM. luteus.
1, S. sahachiroi wild-type strain; 2, AL1001; 3,
AL1002; and 4, AL1003.
(B) HPLC analysis of azinomycin B (solid asterisk)
isolated from wild-type strain (I); AL1001 (II);
AL1002 (III); and AL1003 (IV).
iterative type I PKSs, but also shows the
fourth selective reductive pattern in aro-
matic polyketide biosynthesis governed
by this family (Figure 6): (1) AviM and
CalO5 for OSA biosynthesis (no reduction
step), (2) ChlB1 andMdpB for 6-MSA bio-
synthesis (selective reduction at C5 posi-
tion), (3) NcsB for 2-hydroxy-5-methyl-
NPA biosynthesis (selective reductions
at C5 and C9 positions), and (4) AziB for
relatively hydrophobic 5-methyl-NPA
biosynthesis (selective reductions at C3,
C5, and C9 positions).
These iterative type I PKSs are phylo-
genetically distinct from others (Jenke-
Kodama et al., 2008), indicating an
evolved feature from the ancestor to intrinsically program the
chain elongation in an iterative manner. Sequence analysis
showed that AziB is genetically closer to NcsB, consistent with
the fact that both of them catalyze the biosynthesis of bicyclic
polyketides from one acetyl-CoA and five malonyl-CoAs. Based
on a model for prediction of the stereochemistry of hydroxyacyl
intermediates (Wu et al., 2005; Keatinge-Clay, 2007), similar to
KRs of NcsB, ChlB1 and MdpB, the AziB-KR domain lacks the
H residue at the active site groove and characteristic L-D-Dmotif
(Figure S4), implicating that it falls into a A1 type KR family and
acts on the keto groups to yield L-hydroxy configurations exclu-
sively. Subsequently, cis-double bonds are formed with the de-
hydration activity of the paired DH domain, facilitating the folding
of the resulting polyketide intermediate to furnish the aromatic
structure by aldol condensations. In contrast, the KR domains
of the iterative type I PKS MchA for assembling aliphatic chain
contain the L-D-D motif (Wenzel et al., 2005), consistent with
the predicted D-configuration of the cryptic hydroxyl groups.
Further dehydrations catalyzed by its paired DH domain may
lead to the formation of the conjugated trans-double bonds.
The KR domain of AziB, which acts on the C3, C5, and C9 posi-
tions (Figure 6), offers a regiospecifically distinct and relatively
rich reduction pattern from those of known iterative type I
PKSs, raising an interesting question regarding how these
enzymes biochemically control the selective reductions in the
assembling process of aromatic polyketides.
Previous biochemical studies on the fungal 6-MSA synthases
indicated that the NADPH-dependent reduction and dehydration
occur on the triketide intermediate (Shen, 2000; Moriguchi et al.,
2008). Either in vitro bioassay in the absence of NADPH or in vivo
expression of the KR mutant 6-MSA synthases led to the forma-
tion of a same shunt product, triacetic acid lactone (TAL),
Chemistry & Biology 15, 693–705, July 21, 2008 ª2008 Elsevier Ltd All rights reserved 701
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reacting with the third malonyl-CoA. In contrast, reductive reac-
tions may not be indispensable for extending polyketide chain in
bacterial iterative type I PKSs. For example, AviM and CalO5 that
contain a putative active DH domain (the conserved motif
HxxxGxxxxP identified) but completely omit the KR function
can successively catalyze the decarboxylative condensations
to reach the tetraketide intermediate and form OSA by next cy-
clization/aromatization. Consistent with this catalytic logic,
upon careful HPLC-MS analysis, TAL was not detectable in
each culture broth of the recombinant strains AL1007, AL1008,
or AL1009 for expressing the KR or DH mutant AziB (data not
shown). This result indicated one possibility, that the nonre-
duced triketide intermediate could be further elongated by the
mutant AziBs to form the shunt products that were not identified
under the current analytic condition.
Heterologous expression of AziB alongwith AziB1 andAziB2 in
S. albus led to the production of 3-methoxy-5-methyl-NPA (Fig-
ure 5), supporting that PKS-post modifications on 5-methyl-
NPA precede the skeleton assembly by NRPSs. Although it has
been debated if azinomycins and analogs exhibit the biological
activities through an intercalative or nonintercalative mode of
action, the essentiality of 3-methoxy-5-methyl-NPA is incontro-
vertible: analogs lacking this moiety were biologically inactive
and slight modifications significantly reduced the efficiency for
DNA ISC in vitro.
In the proposed azinomycin B biosynthetic pathway, the un-
usual NRPS system presumably employs four building blocks
Figure 5. Establishment of the Naphthoate Pathway
HPLC analysis of 5-methyl-NPA (solid triangle) and 3-methoxy-5-methyl-NPA
(solid dot) production in the heterologous host S. albus. I, AL1006; II, AL1004;
III, AL1007; IV, Al1008; V, AL1009; VI, 3-methoxy-5-methyl-NPA standard; and
VII, AL1005.702 Chemistry & Biology 15, 693–705, July 21, 2008 ª2008 Elsevie(3-methoxy-5-methyl-NPA 1, a-ketoisovaleric acid 2, aziridino[1,
2a]pyrrolidinyl amino acid 3, and Thr 4) and sequentially con-
denses them to form the azinomycin B skeleton. To reach highly
diverse functionalities, many strategies are adopted in the azino-
mycin B biosynthetic machinery (Figure 3), including (1) pre-
NRPS derivation from amino acids (e.g., building blocks 2 and
3); (2) incorporation of unusual building blocks into the NRPS as-
sembly line (e.g., 1, 2, and 3); (3) NRPS on line modification (e.g.,
conversion of a-ketoisovaleryl group to a-hydroxyisovaleryl
moiety); (4) reductive release of the assembled intermediate as
an aldehyde; and (5) NRPS-post modifications (e.g., oxidation,
epoxidation, and acetylation). These strategies incorporate
a number of novel enzymatic activities. In particular, at least
ten enzymes are likely involved in the biosynthesis of the unprec-
edented azabicyclic ring system. Biochemical investigations of
individual enzymatic functions will allow for the elucidation of
these mechanisms.
SIGNIFICANCE
Azinomycin B is a complex natural product containing
densely assembled functionalities with potent antitumor ac-
tivity. The availability of the azi biosynthetic gene cluster de-
scribedhereprovidesanexcellentopportunity tounderstand
the complex azinomycin B biosynthetic machinery. The find-
ing of AziB as a 5-methyl-NPA synthase adds a newmember
to the pool of bacterial iterative type I PKSs and shows the
fourth selective reductive pattern in aromatic polyketide bio-
synthesis governed by this family. Heterologous expression
established the PKS-post modification route to reach the
first building block, 3-methoxy-5-methyl-NPA. Theproposed
azinomycin B biosynthetic pathway sets the stage to investi-
gate the enzymatic mechanisms for building the structurally
unique and pharmaceutically important groups, including
the unprecedented azabicyclic ring system and highly active
epoxidemoiety. Sincemany of proposed enzymes and reac-
tions are novel, characterization of these will not only enrich
the current knowledge on biosynthetic machineries to make
complex products in nature, but also contribute to the gen-
eral field of combinatorial biosynthesis by expanding the
repertoire of novel genes.
EXPERIMENTAL PROCEDURES
Bacterial Strains, Plasmids, and Reagents
Bacterial strains and plasmids used in this study are summarized in Table S1.
Biochemicals, chemicals, media, restriction enzymes, and other molecular
biological reagents were purchased from standard commercial sources.
DNA Isolation, Manipulation, and Sequencing
DNA isolation and manipulation in E. coli and Streptomyces were carried out
according to standard methods (Kieser et al., 2000; Sambrook and Russell,
2001). PCR amplifications were carried out on an Authorized Thermal Cycler
(Eppendorf AG) using either Taq DNA polymerase or PfuUltra High-Fidelity
DNA polymerase. Primer synthesis and DNA sequencing were performed at
the Shanghai Invitrogen Biotech Co., Ltd., and Chinese National Human
Genome Center.
Genomic Library Construction and Screening
A genomic library of S. sahachiroi NRRL 2485 was constructed in pOJ446
according to the previous protocol (Kieser et al., 2000). E. coli LE392 andr Ltd All rights reserved
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The Azinomycin B Biosynthetic Gene ClusterThe Packagene Lambda DNA Packaging System (Promega) were used for
library construction according to the manufactures’ instructions. For the
PCR product P1 as a probe to screen the library, a 0.9 kb fragment was ampli-
fied by using the primers 50-GCG GAC GGC TAC GGS MGNGGN GAR GG-30
and 50-CGA GCC GTG GCC SGA RAA NAC CCA NAC-30, and confirmed by
sequencing. The genomic library (6.03 103 colonies) was screened by colony
hybridization with P1 and P2 (a 3.2 kb BamHI DNA fragment from cosmid
pAL1022) as probes, and resultant positive clones were further confirmed by
southern hybridization.
Sequence Analysis
The sequence of the azi gene cluster reported in this paper has been deposited
into GenBank under the accession number EU240558. The orfs were deduced
from the sequence with the FramePlot 3.0 beta program (http://watson.nih.go.
jp/jun/cgi-bin/frameplot-3.0b.pl/). The corresponding deduced proteins
were compared with other known proteins in the databases by available
BLAST methods (http://www.ncbi.nlm.nih.gov/blast/). Amino acid sequence
alignments were performed by the CLUSTALW method and the DRAWTREE
and DRAWGRAM methods, respectively, from BIOLOGYWORKBENCH 3.2
software (http://workbench.sdsc.edu/). Prediction of amino acid specificities
Figure 6. Iterative Type I PKSs for Aromatic
Polyketide Biosynthesis in Bacteria
I, AviM and CalO5 for OSA biosynthesis; II, ChlB1
and MadB for 6-MSA biosynthesis; III, NcsB for 2-
hydroxy-5-methyl-NPA biosynthesis; and IV, AziB
for 5-methyl-NPA biosynthesis.
of individual A and AL domains was performed
by using the BLAST server provided at http://
www.nii.res.in/searchall.html.
Production, Isolation, and Analysis of
Azinomycin B in S. sahachiroi
Sporulation and fermentation ofS. sahachiroiwild-
type and mutant strains were carried out accord-
ing to the methods described previously (Kelly
et al., 2008).
For Azinomycin B isolation, each 200 ml culture
was centrifuged at 4C and 3,800 rpm for 10 min.
After removal of the cell pellets, the resulting
supernatant was extracted twice with an equal
volume of methylene chloride. The combined
extract was immediately dried over anhydrous
magnesium sulfate, concentrated in vacuum,
stored at 80C, and resolved in 200 ml methanol
for analysis.
High-performance liquid chromatography–mass
spectrometry (HPLC-MS) analysis was carried out
on an Agilent Rp18 column (4.6 3 250 mm, part
number 880975-902, S/N USCL021611). The col-
umn was equilibrated with 50% solvent A (H2O)
and B (CH3CN) and developed with the following
program: 0–10 min, 80% A/20% B; 10–35 min, a
linear gradient from 80% A/20% B to 20% A/80%
B; 35–37 min, a linear gradient from 20% A/80%
B to 80% A/20% B; and 37–40 min, constant
80% A/20% B. This was carried out at a flow rate
of 0.5 ml/min and UV detection at 218 nm using
an Agilent 1100 HPLC system (Agilent Techno-
logies). The compound with a retention time at
21.4 min showed a [M + H]+ ion at m/z = 624.4 on
a mass spectrometer (Agilent Technologies), con-
sistent with the molecular fomula of azinomycin B
C31H33N3O11. The identity of this compound to
azinomycin B was further confirmed by HPLC-MS/MSn analysis (see the
Supplemental Data).
Production, Isolation, and Analysis
of 5-Methyl-NPA and 3-Methoxy-5-Methyl-NPA in S. albus
Each 500 ml spore suspension (cfu 1.03 108 cells/ml) of the S. albus strain was
inoculated into 100 ml R5A medium (Kieser et al., 2000) in a 500 ml flask and
incubated at 30C and 240 rpm for 5 days. The fermentation culture was
filtered, adjusted pH to 2–3, fragmented by ultrasound (10S/50S) for 15 min,
and then centrifuged to remove the precipitate. The supernatant was extracted
twice with an equal volume of ethyl acetate. After being concentrated in vac-
uum, the extract was resolved in 1 ml methanol for HPLC-MS analysis on
a Phenomenex C18 column (4.6 3 250 nm, part number 00F-3300-E0, S/N
115575-1). The column was equilibrated with 90% solvent A (H2O, 0.1%
TFA) and 10% solvent B (CH3CN, 0.1% TFA), and an analytic method was de-
veloped with the following program at a flow rate of 1ml/min and UV detection
at 218 nm using an Agilent 1100 HPLC system: 0–5 min, a linear gradient from
90%A/10%B to 80%A/20%B; 5–25min, a linear gradient from 80%A/20%B
to 30% A/70% B; 25–26 min, a linear gradient from 30% A/70% B to 5%
A/95% B; 26–29 min, constant 5% A/95% B; and 29–30 min, a linear gradientChemistry & Biology 15, 693–705, July 21, 2008 ª2008 Elsevier Ltd All rights reserved 703
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The Azinomycin B Biosynthetic Gene Clusterfrom 5% A/95% B to 90% A/10% B. The compound with a retention time at
19.6 min showed a [MH] ion at m/z = 185.07, consistent with the molecular
formula of 5-methyl-NPA C12H10O2; the compound with a retention time at
20.5 min showed a [MH] ion at m/z = 215.09, consistent with the molecular
formula of 3-methoxy-5-methyl-NPA C13H12O3.
For purification of 5-methyl-NPA, the extract was subjected to chromatog-
raphy on a silica column (Petroleum ether-ethyl acetate, 4:1) followed by fur-
ther preparation on a Venusil XBP-C18 HPLC column (10 3 250 mm, catalog
number VX952510, S/N XBP-1025070001) under the condition described
above at a flow rate of 3 ml/min. 5-methyl-NPA was obtained as a white pow-
der that exhibited an M+ ion at m/z = 186.0675 upon EI-HRMS analysis, con-
sistent with the molecular formula C12H10O2. The
1H NMR spectrum was mea-
sured on a Varain Mercury 300 (300 MHz) spectrometer. 1H NMR (CD3OD,
s means singlet, d means doublet, and m means multiplet) assignments are
d 2.72 (s, 3H), 7.37 (d, 1H, J = 6.9 Hz), 7.46 (m, 1H), 7.57 (m, 1H), 8.11
(d, 1H, J = 7.2 Hz), 8.25 (d, 1H, J = 8.1 Hz), and 8.67 (d, 1H, J = 9.6 Hz).
Bioassay of Azinomycin B
To detect the biological activities of azinomycin B against M. luteus, each 20 ml
methanol extract described above was added to stainless steel cylinders on
LB agar plates that were preseeded with an overnight M. luteus culture at
a concentration of 1% (vol/vol). The plates were incubated at 37C for 24 hr,
and the biological activity was estimated by measuring the sizes of the inhibi-
tion zones.
SUPPLEMENTAL DATA
Supplemental Data include bacterial strains and plasmids, gene inactivation
and heterologous expression, chemical synthesis, HPLC and HPLC-MS/
MSs analyses, and sequence alignments and can be found with this article
online at http://www.chembiol.com/cgi/content/full/15/7/693/DC1/.
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